VENCLEXTA (venetoclax) in AML: Management & mitigation strategies
~5 mins
In this video, Dr Vinod Pullarkat from the City of Hope National Medical Center, California, US, reviews the management and mitigation strategies that are important when treating acute myeloid leukaemia (AML) patients with VENCLEXTA, including patient preparation and initiating treatment, assessing response, adjusting dose and managing adverse events.
YOU MIGHT ALSO BE INTERESTED IN...
VENCLEXTA in AML:
An Australian Perspective
~6 mins
AML management:
An introduction to VENCLEXTA
~3 mins
VENCLEXTA in AML:
Phase III studies
~6 mins
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
AML: acute myeloid leukaemia.
AU-VENA-210112 September 2022